REVA Medical (ASX:RVA) is a medical device company focused on the development of bioresorbable polymers for vascular applications. Our mission is to restore patient health for life through the application of biomaterials in the development and sale of implantable medical devices.
REVA is a pioneer of novel bioresorbable polycarbonate polymers derived from the naturally occurring tyrosine amino acid. In its 20-year history, the company has developed 19 polymer families. The company’s first commercial polymer is Tyrocore, which was invented for bioresorbable vascular scaffolds. Tyrocore is used to make Fantom Encore, a drug-eluting bioresorbable scaffold for the treatment of coronary artery disease. Fantom Encore is currently available for sale in select European countries.
Cardiovascular disease is the leading cause of death worldwide. Coronary artery disease is a heart condition where the buildup of plaque in the coronary arteries restricts the flow of blood to the heart muscles. Fantom Encore was developed as an alternative to metallic stents to restore blood flow to blocked coronary arteries. Unlike metallic stents, which are a permanent implant, bioresorbable scaffolds are designed to disappear (or “resorb”) from the body over time. This resorption is intended to improve long term outcomes and improve further treatment options for patients.